London AI drug-discovery firm Isomorphic Labs raises $5B in biotech's biggest venture round

Isomorphic Labs, the AI drug-discovery company spun out of Google DeepMind, said on November 17 it has raised a $5 billion Series C round, co-led by Greenoaks and Sequoia Capital. The company, led by Nobel laureate Demis Hassabis, aims to take its AI-designed drug candidates into clinical trials.
Isomorphic Labs, the London-based AI drug-discovery company spun out of Google DeepMind in 2021, said on November 17 it has raised $5 billion in a Series C funding round — reported to be the largest venture round in biotech history. The round was co-led by Greenoaks and Sequoia Capital, with Andreessen Horowitz joining as a new investor; all existing backers took part, including Alphabet's GV and CapitalG, Thrive Capital, MGX, Temasek and the U.K. Sovereign AI Fund.
Third round in 18 months brings total to about $7.7 billion
It is the company's third fundraise since March 2025, when it raised $600 million in its first external round, followed by a $2.1 billion Series B in May. The three rounds total about $7.7 billion. Bloomberg reported on November 4 that the company was seeking a valuation of about $50 billion; Isomorphic Labs did not disclose its new valuation. Industry publications say the round tops the previous biotech record, the $3 billion raised by Altos Labs in 2022.
AI drug-design engine reports positive preclinical results
Isomorphic Labs is building an AI drug-design engine that uses simulation AI models to explore chemistry and design drugs, building on DeepMind's AlphaFold protein-folding AI. The company says its programmes have produced "positive preclinical results" in oncology and immunology, and it has struck deals with pharmaceutical giants including Eli Lilly, Novartis and Johnson & Johnson.
Hassabis now focused full-time on drug discovery
Founder and chief executive Demis Hassabis, who won the Nobel Prize in Chemistry with former DeepMind director John Jumper for the work behind AlphaFold, has stepped down as head of DeepMind to focus on drug discovery and now serves as its chairman. The company said the new funding will go toward developing its drug-design engine, taking drug candidates into clinical trials and expanding into more areas of medicine. No candidate has yet entered human trials. (Sources: TechCrunch; R&D World; Unite.AI; Bloomberg)
(Photo: Demis Hassabis, founder and chief executive of Isomorphic Labs. Image: Isomorphic Labs.)
N環球 
💬 Comments
No comments yet. Be the first!